Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Express Scripts
McKesson
Medtronic
Baxter

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Netarsudil dimesylate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for netarsudil dimesylate and what is the scope of patent protection?

Netarsudil dimesylate is the generic ingredient in one branded drug marketed by Aerie Pharms Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Netarsudil dimesylate has forty-three patent family members in seven countries.

One supplier is listed for this compound.

Summary for netarsudil dimesylate
International Patents:43
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
DailyMed Link:netarsudil dimesylate at DailyMed
Pharmacology for netarsudil dimesylate
Drug ClassRho Kinase Inhibitor
Mechanism of ActionRho Kinase Inhibitors

US Patents and Regulatory Information for netarsudil dimesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Aerie Pharms Inc RHOPRESSA netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.